<DOC>
	<DOCNO>NCT01878448</DOCNO>
	<brief_summary>Anlotibib ( ALTN ) kind innovative medicine approve State Food Drug Administration（SFDA） research Jiangsu Chia-tai Tianqing Pharmaceutical Co. , Ltd. ALTN kinase inhibitor receptor tyrosine multi-targets , especially VEGFR2 VEGFR3 . It obvious resistance new angiogenesis . The protocol explore ALTN effectiveness advance soft tissue sarcoma security .</brief_summary>
	<brief_title>A Phase II Study Anlotinib STS Patients</brief_title>
	<detailed_description />
	<criteria>1.Faild introditional treatmeat , Mainly include : MFH/liposarcoma/leiomyosarcoma/SS others ( MPNST/Fibrosarcoma/CCS/ASPS/AS/ES ; 2.Receiveed least one chemotherapy regimens treatment ; 3.1870years , ECOG:02 , Expected survival period &gt; 3 month ; 4.HB≥100g/L , ANC ( Absolute Neutrophil Count ) ≥1.5×109/L；PLT 80×109/L , BIL/Cr normal range , ALT/AST ( aspartate aminotransferase ) ≤1.5*ULN ( hepatic metastasis , ALT/AST ( aspartate aminotransferase ) ≤5*ULN ) ; TG≤ 3.0mmol/L，cholesterol≤7.75mmol/L ; LVEF LLN . 5.Used contraceptive study 6 month ; 6.Volunteer . 1 . Received vascular endothelial growth inhibitor type target therapy ; 2.With second cancer ; 3.Participated clinical trial four week ; 4.Received radiotherapy chemotherapy treatment four week ; 5.AE &gt; 1 6.Has influence oral drug ; 7.Brain metastasis , spinal cord compression , cancerous meningitis ; 8.Any serious fail control disease 9.Artery/venous thrombotic ; 10.Coagulant function abnormality ; 11.Arteriovenous thrombosis event ; 12.Hitory psychiatric drug abuse mental disorder ; 13.Immunodeficiency history ; 14.Concomitant disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>